25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CADL (Candel Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Candel Therapeutics Inc together

I guess you are interested in Candel Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Candel Therapeutics Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Candel Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Candel Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Candel Therapeutics Inc

I send you an email if I find something interesting about Candel Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Candel Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Candel Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.36
Expected worth in 1 year
$2.61
How sure are you?
19.0%

+ What do you gain per year?

Total Gains per Share
$1.24
Return On Investment
25.7%

For what price can you sell your share?

Current Price per Share
$4.85
Expected price per share
$4.3384 - $6.31
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Candel Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$4.85
Intrinsic Value Per Share
$-4.40 - $-5.02
Total Value Per Share
$-3.03 - $-3.66

2.2. Growth of Candel Therapeutics Inc (5 min.)




Is Candel Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$74.6m$18.1m$10.8m37.4%

How much money is Candel Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$9.8m-$9.3m-$553k-5.6%
Net Profit Margin0.0%-271.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Candel Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#376 / 884

Most Revenue
#695 / 884

Most Profit
#524 / 884

Most Efficient
#311 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Candel Therapeutics Inc?

Welcome investor! Candel Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Candel Therapeutics Inc.

First you should know what it really means to hold a share of Candel Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Candel Therapeutics Inc is $4.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Candel Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Candel Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.36. Based on the TTM, the Book Value Change Per Share is $0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Candel Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.132.8%-0.20-4.1%-0.19-3.8%-0.17-3.6%-0.16-3.2%-0.15-3.1%
Usd Book Value Change Per Share0.040.8%0.316.4%-0.17-3.5%0.010.2%0.071.4%0.061.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.040.8%0.316.4%-0.17-3.5%0.010.2%0.071.4%0.061.3%
Usd Price Per Share5.65-6.87-1.31-3.52-3.30-3.14-
Price to Earnings Ratio10.48--2.22--1.77--3.05--2.83--2.69-
Price-to-Total Gains Ratio142.28-15.61--7.98--5.17--26.42--26.42-
Price to Book Ratio4.14--10.80-5.77--0.90-0.40-0.38-
Price-to-Total Gains Ratio142.28-15.61--7.98--5.17--26.42--26.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.85
Number of shares206
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.310.07
Usd Total Gains Per Share0.310.07
Gains per Quarter (206 shares)64.0814.04
Gains per Year (206 shares)256.3056.18
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1025624605646
205135020112102
307697580169158
40102510140225214
50128212700281270
60153815260337326
70179417820393382
80205020380449438
90230722940506494
100256325500562550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%2.019.00.09.5%2.019.00.09.5%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%4.014.02.020.0%4.014.03.019.0%4.014.03.019.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%4.014.02.020.0%4.014.03.019.0%4.014.03.019.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Candel Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0400.311-87%-0.168+523%0.008+424%0.068-42%0.065-39%
Book Value Per Share--1.3640.546+150%0.362+277%0.635+115%0.477+186%0.454+200%
Current Ratio--4.6412.554+82%3.876+20%6.551-29%7.544-38%7.184-35%
Debt To Asset Ratio--0.2210.922-76%0.630-65%0.645-66%0.727-70%0.693-68%
Debt To Equity Ratio--0.2840.224+27%2.144-87%0.946-70%0.643-56%0.612-54%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--380362007.300374999473.575+1%77217280.250+393%204621143.275+86%254326656.287+50%254326656.287+50%
Eps--0.135-0.201+249%-0.186+238%-0.173+229%-0.157+216%-0.151+212%
Ev To Ebitda Ratio---11.696-8.160-30%-2.327-80%-5.876-50%-2.336-80%-2.336-80%
Free Cash Flow Per Share---0.157-0.132-16%-0.161+2%-0.157-1%-0.134-15%-0.130-17%
Free Cash Flow To Equity Per Share---0.1920.336-157%-0.167-13%0.030-728%0.070-374%0.064-397%
Gross Profit Margin--1.0001.0020%1.0000%1.0010%1.0000%1.0000%
Intrinsic Value_10Y_max---5.021----------
Intrinsic Value_10Y_min---4.396----------
Intrinsic Value_1Y_max---0.609----------
Intrinsic Value_1Y_min---0.598----------
Intrinsic Value_3Y_max---1.750----------
Intrinsic Value_3Y_min---1.672----------
Intrinsic Value_5Y_max---2.793----------
Intrinsic Value_5Y_min---2.599----------
Market Cap242998095.000-27%309427007.300350541723.575-12%65509280.250+372%178431809.942+73%166556042.215+86%158624802.110+95%
Net Profit Margin----0%-2.7190%6.115-100%-68.5790%-68.0360%
Operating Margin----0%-2.5190%-55.8180%-91.9750%-90.2060%
Operating Ratio----0%2.565-100%72.231-100%137.556-100%136.854-100%
Pb Ratio3.557-16%4.144-10.802+361%5.768-28%-0.902+122%0.395+949%0.376+1001%
Pe Ratio8.999-16%10.483-2.222+121%-1.769+117%-3.050+129%-2.829+127%-2.694+126%
Price Per Share4.850-16%5.6506.865-18%1.308+332%3.518+61%3.298+71%3.141+80%
Price To Free Cash Flow Ratio-7.704+14%-8.975-13.347+49%-2.061-77%-6.305-30%-5.955-34%-5.671-37%
Price To Total Gains Ratio122.131-16%142.27615.609+812%-7.981+106%-5.166+104%-26.416+119%-26.416+119%
Quick Ratio--4.5922.486+85%3.729+23%6.375-28%7.370-38%7.019-35%
Return On Assets--0.077-0.347+551%-0.215+380%-0.195+353%-0.169+319%-0.161+309%
Return On Equity--0.099-0.028+129%-0.731+840%-0.285+388%-0.183+285%-0.177+279%
Total Gains Per Share--0.0400.311-87%-0.168+523%0.008+424%0.068-42%0.065-39%
Usd Book Value--74675000.00028943250.000+158%18129250.000+312%32321250.000+131%24225350.000+208%23071761.905+224%
Usd Book Value Change Per Share--0.0400.311-87%-0.168+523%0.008+424%0.068-42%0.065-39%
Usd Book Value Per Share--1.3640.546+150%0.362+277%0.635+115%0.477+186%0.454+200%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--380362007.300374999473.575+1%77217280.250+393%204621143.275+86%254326656.287+50%254326656.287+50%
Usd Eps--0.135-0.201+249%-0.186+238%-0.173+229%-0.157+216%-0.151+212%
Usd Free Cash Flow---8619000.000-6803250.000-21%-8047250.000-7%-7904250.000-8%-6773050.000-21%-6555952.381-24%
Usd Free Cash Flow Per Share---0.157-0.132-16%-0.161+2%-0.157-1%-0.134-15%-0.130-17%
Usd Free Cash Flow To Equity Per Share---0.1920.336-157%-0.167-13%0.030-728%0.070-374%0.064-397%
Usd Market Cap242998095.000-27%309427007.300350541723.575-12%65509280.250+372%178431809.942+73%166556042.215+86%158624802.110+95%
Usd Price Per Share4.850-16%5.6506.865-18%1.308+332%3.518+61%3.298+71%3.141+80%
Usd Profit--7379000.000-9894250.000+234%-9341250.000+227%-6927083.333+194%-6395950.000+187%-6175761.905+184%
Usd Revenue----0%888000.000-100%303750.000-100%194650.000-100%186857.143-100%
Usd Total Gains Per Share--0.0400.311-87%-0.168+523%0.008+424%0.068-42%0.065-39%
 EOD+3 -5MRQTTM+15 -18YOY+27 -73Y+22 -145Y+18 -1710Y+18 -17

3.3 Fundamental Score

Let's check the fundamental score of Candel Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-158.999
Price to Book Ratio (EOD)Between0-13.557
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.592
Current Ratio (MRQ)Greater than14.641
Debt to Asset Ratio (MRQ)Less than10.221
Debt to Equity Ratio (MRQ)Less than10.284
Return on Equity (MRQ)Greater than0.150.099
Return on Assets (MRQ)Greater than0.050.077
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Candel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.413
Ma 20Greater thanMa 505.229
Ma 50Greater thanMa 1005.194
Ma 100Greater thanMa 2006.398
OpenGreater thanClose4.950
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Candel Therapeutics Inc

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the"enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-19 01:46:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Candel Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Candel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-271.9%+271.9%
TTM-5Y-6,857.9%+6,857.9%
5Y-6,857.9%10Y-6,803.6%-54.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM--141.4%+141.4%
YOY-271.9%-186.1%-85.8%
3Y611.5%-248.3%+859.8%
5Y-6,857.9%-338.6%-6,519.3%
10Y-6,803.6%-488.9%-6,314.7%
4.3.1.2. Return on Assets

Shows how efficient Candel Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • 7.7% Return on Assets means that Candel Therapeutics Inc generated $0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Candel Therapeutics Inc:

  • The MRQ is 7.7%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -34.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ7.7%TTM-34.7%+42.4%
TTM-34.7%YOY-21.5%-13.2%
TTM-34.7%5Y-16.9%-17.8%
5Y-16.9%10Y-16.1%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7%-11.5%+19.2%
TTM-34.7%-11.6%-23.1%
YOY-21.5%-11.4%-10.1%
3Y-19.5%-11.8%-7.7%
5Y-16.9%-12.1%-4.8%
10Y-16.1%-13.8%-2.3%
4.3.1.3. Return on Equity

Shows how efficient Candel Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • 9.9% Return on Equity means Candel Therapeutics Inc generated $0.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Candel Therapeutics Inc:

  • The MRQ is 9.9%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -2.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ9.9%TTM-2.8%+12.7%
TTM-2.8%YOY-73.1%+70.3%
TTM-2.8%5Y-18.3%+15.5%
5Y-18.3%10Y-17.7%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9%-13.6%+23.5%
TTM-2.8%-14.9%+12.1%
YOY-73.1%-14.4%-58.7%
3Y-28.5%-17.0%-11.5%
5Y-18.3%-17.9%-0.4%
10Y-17.7%-20.1%+2.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Candel Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Candel Therapeutics Inc is operating .

  • Measures how much profit Candel Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Candel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-251.9%+251.9%
TTM-5Y-9,197.5%+9,197.5%
5Y-9,197.5%10Y-9,020.6%-176.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--250.3%+250.3%
YOY-251.9%-205.1%-46.8%
3Y-5,581.8%-220.2%-5,361.6%
5Y-9,197.5%-342.6%-8,854.9%
10Y-9,020.6%-475.5%-8,545.1%
4.3.2.2. Operating Ratio

Measures how efficient Candel Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.565-2.565
TTM-5Y137.556-137.556
5Y137.55610Y136.854+0.702
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM-2.704-2.704
YOY2.5653.063-0.498
3Y72.2313.576+68.655
5Y137.5564.713+132.843
10Y136.8546.512+130.342
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Candel Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Candel Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.64 means the company has $4.64 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 4.641. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.554. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ4.641TTM2.554+2.087
TTM2.554YOY3.876-1.322
TTM2.5545Y7.544-4.989
5Y7.54410Y7.184+0.359
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6413.661+0.980
TTM2.5543.786-1.232
YOY3.8764.121-0.245
3Y6.5514.680+1.871
5Y7.5445.765+1.779
10Y7.1846.150+1.034
4.4.3.2. Quick Ratio

Measures if Candel Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.59 means the company can pay off $4.59 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 4.592. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.486. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.592TTM2.486+2.106
TTM2.486YOY3.729-1.243
TTM2.4865Y7.370-4.884
5Y7.37010Y7.019+0.351
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5922.826+1.766
TTM2.4863.128-0.642
YOY3.7293.782-0.053
3Y6.3754.304+2.071
5Y7.3705.703+1.667
10Y7.0196.454+0.565
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Candel Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Candel Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Candel Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22 means that Candel Therapeutics Inc assets are financed with 22.1% credit (debt) and the remaining percentage (100% - 22.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 0.221. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.922. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.221TTM0.922-0.700
TTM0.922YOY0.630+0.292
TTM0.9225Y0.727+0.194
5Y0.72710Y0.693+0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2210.324-0.103
TTM0.9220.347+0.575
YOY0.6300.327+0.303
3Y0.6450.339+0.306
5Y0.7270.349+0.378
10Y0.6930.382+0.311
4.5.4.2. Debt to Equity Ratio

Measures if Candel Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 28.4% means that company has $0.28 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 0.284. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.224. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.284TTM0.224+0.060
TTM0.224YOY2.144-1.920
TTM0.2245Y0.643-0.419
5Y0.64310Y0.612+0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2840.383-0.099
TTM0.2240.436-0.212
YOY2.1440.410+1.734
3Y0.9460.446+0.500
5Y0.6430.460+0.183
10Y0.6120.509+0.103
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Candel Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 10.48 means the investor is paying $10.48 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Candel Therapeutics Inc:

  • The EOD is 8.999. Based on the earnings, the company is underpriced. +1
  • The MRQ is 10.483. Based on the earnings, the company is underpriced. +1
  • The TTM is -2.222. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.999MRQ10.483-1.484
MRQ10.483TTM-2.222+12.705
TTM-2.222YOY-1.769-0.453
TTM-2.2225Y-2.829+0.607
5Y-2.82910Y-2.694-0.135
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.999-2.197+11.196
MRQ10.483-2.027+12.510
TTM-2.222-2.527+0.305
YOY-1.769-3.733+1.964
3Y-3.050-3.717+0.667
5Y-2.829-6.036+3.207
10Y-2.694-6.649+3.955
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Candel Therapeutics Inc:

  • The EOD is -7.704. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.975. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -13.347. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.704MRQ-8.975+1.271
MRQ-8.975TTM-13.347+4.372
TTM-13.347YOY-2.061-11.286
TTM-13.3475Y-5.955-7.392
5Y-5.95510Y-5.671-0.284
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.704-3.007-4.697
MRQ-8.975-2.704-6.271
TTM-13.347-3.627-9.720
YOY-2.061-4.334+2.273
3Y-6.305-5.070-1.235
5Y-5.955-8.532+2.577
10Y-5.671-9.305+3.634
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Candel Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.14 means the investor is paying $4.14 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Candel Therapeutics Inc:

  • The EOD is 3.557. Based on the equity, the company is fair priced.
  • The MRQ is 4.144. Based on the equity, the company is fair priced.
  • The TTM is -10.802. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD3.557MRQ4.144-0.587
MRQ4.144TTM-10.802+14.946
TTM-10.802YOY5.768-16.570
TTM-10.8025Y0.395-11.197
5Y0.39510Y0.376+0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.5571.921+1.636
MRQ4.1441.843+2.301
TTM-10.8022.113-12.915
YOY5.7682.467+3.301
3Y-0.9022.541-3.443
5Y0.3953.666-3.271
10Y0.3764.311-3.935
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Candel Therapeutics Inc.

4.8.1. Institutions holding Candel Therapeutics Inc

Institutions are holding 42.644% of the shares of Candel Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31FMR Inc14.14160.00267085316316171780.5821
2025-03-31Baker Bros Advisors LP4.86440.15242437189-544794-18.2695
2025-03-31BlackRock Inc3.52030.0002176377057982348.9737
2025-03-31Vanguard Group Inc3.46510.0002173610439695429.6422
2025-03-31Portolan Capital Management, LLC1.75880.378488118412743916.9074
2025-03-31Halter Ferguson Financial Inc1.38352.0047693153118191.7347
2025-03-31Geode Capital Management, LLC1.37210.000368746123203750.9497
2025-03-31State Street Corp1.12450.000156340424350.4341
2025-03-31Sands Capital Ventures, LLC0.810.560840583700
2024-12-31Susquehanna International Group, LLP0.58770.0004294443158988117.3733
2025-03-31Northern Trust Corp0.47010.00022355367051542.7309
2025-03-31Marshall Wace Asset Management Ltd0.46820.00172345972345970
2025-03-31Franklin Resources Inc0.42120.00032110142110140
2025-03-31Millennium Management LLC0.41640.0006208609176983559.6123
2025-03-31Bank of America Corp0.35780.0001179251112440168.2956
2024-12-31UBS Group AG0.3130.00031568061473601560.0254
2025-03-31HB Wealth Management, LLC0.18820.00459430070008.0183
2025-03-31Charles Schwab Investment Management Inc0.16740.0001838803169060.7204
2025-03-31Squarepoint Ops LLC0.14980.00057507855767288.7836
2024-12-31Nuveen Asset Management, LLC0.13620.00026822620093.034
Total 36.11633.108618095158+5175793+28.6%

4.9.2. Funds holding Candel Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Fidelity Select Biotechnology11.06720.6979554497900
2025-04-30Vanguard Total Stock Mkt Idx Inv1.72970.000386665000
2025-04-30Fidelity Growth Compy Commingled Pl S1.40530.0043704102469687.1474
2025-05-31iShares Russell 2000 ETF1.39440.006269861100
2025-04-30Strategic Advisers U.S. Total Stock1.23960.00416210948969416.8788
2025-04-30Fidelity Growth Company Fund1.05960.0044530868335006.7355
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.9770.002448952400
2024-12-31BANOR SICAV Rosemary S EUR Acc0.71859.7213360000-39131-9.804
2025-03-31Fidelity Small Cap Index0.56740.00662842946916132.148
2025-05-31iShares Russell 2000 Growth ETF0.48250.011924172700
2025-04-30Fidelity Extended Market Index0.34290.0023171807-1642-0.9467
2025-04-30Fidelity Growth Company K60.32990.0046165297108006.9904
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.32550.002216310000
2025-02-28Aesculape SRI IC0.28240.74471415001382910.8317
2025-04-30Vanguard Russell 2000 ETF0.28040.005814050678965.9543
2025-04-30Fidelity Series Growth Company0.27830.0041139441102417.9265
2025-03-31Vanguard US Momentum Factor ETF0.2630.077913178983606.7731
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.23370.00741171003870049.3622
2025-04-30Schwab Small Cap Index0.13750.00586888000
2025-03-31NT R2000 Index Fund - NL0.13680.0067685542013541.5849
Total 23.251611.320911649823+308511+2.6%

5.3. Insider Transactions

Insiders are holding 20.834% of the shares of Candel Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-03-17Seshu TyagarajanSELL312788.82
2025-03-17Charles SchochSELL50008.83
2025-01-15Francesca BaroneSELL135347.22
2025-01-15Seshu TyagarajanSELL143227.22
2025-01-08Francesca BaroneSELL136738.22
2024-12-16Paul B ManningBUY12500006
2024-11-29Seshu TyagarajanSELL203924.56
2024-11-29William Garrett NicholsSELL139354.56
2024-10-14Estuardo Aguilar-cordovaSELL150006.02
2024-10-11Estuardo Aguilar-cordovaSELL150006.05
2024-10-03Estuardo Aguilar-cordovaSELL18006.85
2024-07-17Charles SchochSELL98846.47
2024-07-17Paul Peter TakSELL225286.47
2024-07-17Seshu TyagarajanSELL148516.47
2024-07-11Charles SchochSELL88975.97
2024-07-11Paul Peter TakSELL202935.97
2024-07-11Seshu TyagarajanSELL133305.97
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Income before Tax  -8,221-14,016-22,23711,591-10,646-3,427-14,07321,4527,379
Net Income  -8,221-14,016-22,23711,591-10,646-3,427-14,07321,4527,379
Net Interest Income  -326-1-32776-251151-100728628
Total Other Income Expense Net -319-13,347-13,66611,777-1,889-4,043-5,93221,44115,509
Net Income from Continuing Operations  -8,221-14,016-22,23711,591-10,646-3,427-14,07321,4527,379



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets95,905
Total Liabilities21,230
Total Stockholder Equity74,675
 As reported
Total Liabilities 21,230
Total Stockholder Equity+ 74,675
Total Assets = 95,905

Assets

Total Assets95,905
Total Current Assets93,148
Long-term Assets2,757
Total Current Assets
Cash And Cash Equivalents 92,165
Other Current Assets 983
Total Current Assets  (as reported)93,148
Total Current Assets  (calculated)93,148
+/-0
Long-term Assets
Property Plant Equipment 2,433
Long-term Assets Other 324
Long-term Assets  (as reported)2,757
Long-term Assets  (calculated)2,757
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,069
Long-term Liabilities1,161
Total Stockholder Equity74,675
Total Current Liabilities
Short-term Debt 9,752
Short Long Term Debt 9,172
Accounts payable 760
Other Current Liabilities 8,797
Total Current Liabilities  (as reported)20,069
Total Current Liabilities  (calculated)28,481
+/- 8,412
Long-term Liabilities
Capital Lease Obligations 837
Long-term Liabilities  (as reported)1,161
Long-term Liabilities  (calculated)837
+/- 324
Total Stockholder Equity
Common Stock493
Retained Earnings -184,826
Other Stockholders Equity 259,008
Total Stockholder Equity (as reported)74,675
Total Stockholder Equity (calculated)74,675
+/-0
Other
Capital Stock493
Cash and Short Term Investments 92,165
Common Stock Shares Outstanding 54,766
Liabilities and Stockholders Equity 95,905
Net Debt -82,156
Net Invested Capital 84,751
Net Working Capital 73,079
Property Plant and Equipment Gross 5,753
Short Long Term Debt Total 10,009



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
38,282
35,094
30,744
95,960
89,205
101,562
93,301
85,007
77,691
67,238
58,708
50,061
41,702
31,217
26,485
21,517
106,866
95,905
95,905106,86621,51726,48531,21741,70250,06158,70867,23877,69185,00793,301101,56289,20595,96030,74435,09438,282000
   > Total Current Assets 
45,057
0
0
35,146
29,471
24,426
90,950
84,945
95,646
87,326
79,070
71,945
61,875
53,362
45,101
36,797
27,136
22,735
18,085
103,804
93,148
93,148103,80418,08522,73527,13636,79745,10153,36261,87571,94579,07087,32695,64684,94590,95024,42629,47135,1460045,057
       Cash And Cash Equivalents 
-45,057
0
0
35,053
29,152
24,316
88,385
82,642
94,321
86,782
77,183
70,058
59,258
51,894
42,983
35,413
25,713
21,454
16,558
102,654
92,165
92,165102,65416,55821,45425,71335,41342,98351,89459,25870,05877,18386,78294,32182,64288,38524,31629,15235,05300-45,057
       Short-term Investments 
90,114
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000090,114
       Other Current Assets 
0
0
0
93
319
110
2,565
4,606
2,650
1,088
3,774
1,887
2,617
1,468
2,118
1,384
1,423
1,281
1,527
1,150
983
9831,1501,5271,2811,4231,3842,1181,4682,6171,8873,7741,0882,6504,6062,56511031993000
   > Long-term Assets 
-45,057
0
0
3,136
5,623
6,318
5,010
4,260
5,916
5,975
5,937
5,746
5,363
5,346
4,960
4,905
4,081
3,750
3,432
3,062
2,757
2,7573,0623,4323,7504,0814,9054,9605,3465,3635,7465,9375,9755,9164,2605,0106,3185,6233,13600-45,057
       Property Plant Equipment 
0
0
0
2,787
4,263
4,606
4,587
3,836
5,479
5,709
5,671
5,480
5,097
4,921
4,555
4,022
3,713
3,403
3,091
2,733
2,433
2,4332,7333,0913,4033,7134,0224,5554,9215,0975,4805,6715,7095,4793,8364,5874,6064,2632,787000
       Long-term Assets Other 
-45,057
0
0
349
937
1,712
423
424
437
266
266
266
266
159
139
116
102
347
341
329
324
3243293413471021161391592662662662664374244231,71293734900-45,057
> Total Liabilities 
0
0
0
61,844
62,591
73,919
32,973
25,068
37,800
33,229
32,880
29,977
27,586
27,937
27,039
28,957
25,238
36,457
36,774
40,539
21,230
21,23040,53936,77436,45725,23828,95727,03927,93727,58629,97732,88033,22937,80025,06832,97373,91962,59161,844000
   > Total Current Liabilities 
0
0
0
4,713
5,498
4,494
4,397
5,362
5,472
5,878
5,898
5,615
5,236
8,163
10,327
14,184
13,537
13,996
15,268
37,529
20,069
20,06937,52915,26813,99613,53714,18410,3278,1635,2365,6155,8985,8785,4725,3624,3974,4945,4984,713000
       Short-term Debt 
0
0
0
463
464
3,448
3,212
0
858
880
904
928
1,729
4,140
7,100
9,406
10,293
10,887
10,403
10,461
9,752
9,75210,46110,40310,88710,2939,4067,1004,1401,72992890488085803,2123,448464463000
       Short Long Term Debt 
0
0
0
463
464
0
0
0
0
0
0
0
1,253
3,652
6,100
8,893
9,767
9,809
9,851
9,895
9,172
9,1729,8959,8519,8099,7678,8936,1003,6521,2530000000464463000
       Accounts payable 
0
0
0
921
1,513
759
925
1,590
1,386
1,584
970
380
592
480
250
422
472
433
296
237
760
7602372964334724222504805923809701,5841,3861,5909257591,513921000
       Other Current Liabilities 
0
0
0
3,329
3,521
224
229
3,772
3,228
3,414
4,024
4,307
2,915
3,543
2,977
4,356
2,772
2,676
4,569
26,831
8,797
8,79726,8314,5692,6762,7724,3562,9773,5432,9154,3074,0243,4143,2283,7722292243,5213,329000
   > Long-term Liabilities 
0
0
0
57,131
57,093
69,425
28,576
19,706
32,328
27,351
26,982
24,362
22,350
19,774
16,712
14,773
11,701
22,461
21,506
3,010
1,161
1,1613,01021,50622,46111,70114,77316,71219,77422,35024,36226,98227,35132,32819,70628,57669,42557,09357,131000
       Long term Debt Total 
0
0
0
0
0
521
541
560
20,525
20,630
0
0
19,697
0
0
0
0
0
0
0
0
0000000019,6970020,63020,52556054152100000
       Warrants
0
0
0
0
0
49,060
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000049,06000000
       Other Liabilities 
0
0
0
0
7,531
19,844
28,035
19,146
9,965
4,996
4,626
2,026
0
1,134
0
0
0
0
0
0
0
00000001,13402,0264,6264,9969,96519,14628,03519,8447,5310000
       Deferred Long Term Liability 
0
0
0
0
937
1,300
585
894
0
0
0
0
132
0
0
0
0
0
0
0
0
0000000013200008945851,3009370000
> Total Stockholder Equity
41,022
0
0
-23,562
-27,497
-43,175
62,987
64,137
63,762
60,072
52,127
-99,089
39,652
30,771
23,022
12,745
5,979
-9,972
-15,257
66,327
74,675
74,67566,327-15,257-9,9725,97912,74523,02230,77139,652-99,08952,12760,07263,76264,13762,987-43,175-27,497-23,5620041,022
   Common Stock
0
0
0
116
117
117
286
286
287
290
290
290
290
290
290
290
292
303
322
469
493
493469322303292290290290290290290290287286286117117116000
   Retained Earnings -184,826-192,205-178,132-167,486-145,249-137,028-125,933-117,498-107,884-99,089-94,006-85,318-81,169-80,295-81,891-65,729-48,649-44,171000
   Capital Surplus 
0
0
0
0
0
22,437
144,592
144,146
144,644
145,548
0
0
147,694
0
0
0
0
0
0
0
0
00000000147,69400145,548144,644144,146144,59222,43700000
   Treasury Stock00000000-44800-448000000000
   Other Stockholders Equity 
0
0
0
69,553
21,195
22,437
144,592
144,146
144,644
145,100
145,843
146,513
147,246
147,979
148,665
149,483
150,936
157,211
162,553
258,063
259,008
259,008258,063162,553157,211150,936149,483148,665147,979147,246146,513145,843145,100144,644144,146144,59222,43721,19569,553000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-990
Gross Profit0-990
 
Operating Income (+$)
Gross Profit0
Operating Expense-33,371
Operating Income-33,371-33,371
 
Operating Expense (+$)
Research Development19,314
Selling General Administrative14,057
Selling And Marketing Expenses0
Operating Expense33,37133,371
 
Net Interest Income (+$)
Interest Income1,086
Interest Expense-2,090
Other Finance Cost-0
Net Interest Income-1,004
 
Pretax Income (+$)
Operating Income-33,371
Net Interest Income-1,004
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-55,177-11,565
EBIT - interestExpense = -55,177
-55,177
-53,087
Interest Expense2,090
Earnings Before Interest and Taxes (EBIT)-53,087-53,087
Earnings Before Interest and Taxes (EBITDA)-52,097
 
After tax Income (+$)
Income Before Tax-55,177
Tax Provision-0
Net Income From Continuing Ops-55,177-55,177
Net Income-55,177
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-21,8061,004
 

Technical Analysis of Candel Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Candel Therapeutics Inc. The general trend of Candel Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Candel Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Candel Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Candel Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.1961 < 6.289 < 6.31.

The bearish price targets are: 4.48 > 4.41 > 4.3384.

Know someone who trades $CADL? Share this with them.👇

Candel Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Candel Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Candel Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Candel Therapeutics Inc. The current macd is -0.15779514.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Candel Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Candel Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Candel Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Candel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCandel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Candel Therapeutics Inc. The current adx is 13.12.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Candel Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Candel Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Candel Therapeutics Inc. The current sar is 4.4952.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Candel Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Candel Therapeutics Inc. The current rsi is 42.41. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Candel Therapeutics Inc Daily Relative Strength Index (RSI) ChartCandel Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Candel Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Candel Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Candel Therapeutics Inc Daily Stochastic Oscillator ChartCandel Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Candel Therapeutics Inc. The current cci is -74.29494514.

Candel Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCandel Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Candel Therapeutics Inc. The current cmo is -18.49728604.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Candel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCandel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Candel Therapeutics Inc. The current willr is -73.94366197.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Candel Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Candel Therapeutics Inc Daily Williams %R ChartCandel Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Candel Therapeutics Inc.

Candel Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Candel Therapeutics Inc. The current atr is 0.35535014.

Candel Therapeutics Inc Daily Average True Range (ATR) ChartCandel Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Candel Therapeutics Inc. The current obv is 413,397,465.

Candel Therapeutics Inc Daily On-Balance Volume (OBV) ChartCandel Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Candel Therapeutics Inc. The current mfi is 27.05.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Candel Therapeutics Inc Daily Money Flow Index (MFI) ChartCandel Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Candel Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-10MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Candel Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Candel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.413
Ma 20Greater thanMa 505.229
Ma 50Greater thanMa 1005.194
Ma 100Greater thanMa 2006.398
OpenGreater thanClose4.950
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Candel Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Candel Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Candel Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Candel Therapeutics Inc

I send you an email if I find something interesting about Candel Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Candel Therapeutics Inc.

Receive notifications about Candel Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.